Posaconazole in the management of refractory invasive fungal infections

References

• AkinsRA2005An update on antifungal targets and mechanisms of resistance in Candida albicansMed Mycol4328531816110776
   PubMed Web of Science ®Google Scholar
• AnsteadGMCorcoranGLewisJ2005Refractory coccidioidomycosis treated with posaconazoleClin Infect Dis401770615909265
   PubMed Web of Science ®Google Scholar
• BaranJJrMuckatiraBKhatibR2001Candidemia before and during the fluconazole era: prevalence, type of species and approach to treatment in a tertiary care community hospitalScand J Infect Dis33137911233850
   PubMedGoogle Scholar
• BarnesPDMarrKA2007Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipientsBr J Haematol1395193117979942
   PubMed Web of Science ®Google Scholar
• Carrillo-MunozAJQuindosGRuesgaM2005Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infectionsJ Antimicrob Chemother553171915705637
   PubMed Web of Science ®Google Scholar
• CatanzaroACloudGAStevensDA2007Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosisClin Infect Dis45562817682989
   PubMed Web of Science ®Google Scholar
• ChauASMendrickCASabatelliFJ2004Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azolesAntimicrob Agents Chemother4821243115155210
   PubMed Web of Science ®Google Scholar
• CornelyOAMaertensJWinstonDJ2007Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropeniaN Engl J Med3563485917251531
   PubMed Web of Science ®Google Scholar
• CourtneyRDLaughlinMGontzH2000Single-dose pharmacokinetics of posaconazole in subjects with various degrees of chronic liver disease [abstract]. AAPS PharmSci, AAPS Annual Meeting Supplement Abstract 3495.
   Google Scholar
• CourtneyRPaiSLaughlinM2003Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adultsAntimicrob Agents Chemother4727889512936975
   PubMed Web of Science ®Google Scholar
• CourtneyRRadwanskiELimJ2004Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy menAntimicrob Agents Chemother48804814982768
   PubMed Web of Science ®Google Scholar
• CourtneyRSansoneASmithW2005Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal diseaseJ Clin Pharmacol451859215647411
   PubMed Web of Science ®Google Scholar
• Cuenca-EstrellaMGomez-LopezAMelladoE2006Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungiAntimicrob Agents Chemother509172116495251
   PubMed Web of Science ®Google Scholar
• DannaouiEMeletiadisJMoutonJW2003In vitro susceptibilities of zygomycetes to conventional and new antifungalsJ Antimicrob Chemother51455212493786
   PubMed Web of Science ®Google Scholar
• DiekemaDJMesserSAHollisRJ2003Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungiJ Clin Microbiol413623612904365
   PubMed Web of Science ®Google Scholar
• Espinel-IngroffA2003In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literatureRev Iberoam Micol201213615456349
   PubMedGoogle Scholar
• EzzetFWexlerDCourtneyR2005Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendationsClin Pharmacokinet442112015656699
   PubMed Web of Science ®Google Scholar
• FichtenbaumCJPowderlyWG1998Refractory mucosal candidiasis in patients with human immunodeficiency virus infectionClin Infect Dis26556659524822
   PubMed Web of Science ®Google Scholar
• GalgianiJNCatanzaroACloudGA2000Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study GroupAnn Intern Med1336768611074900
   PubMed Web of Science ®Google Scholar
• GhosalAHapangamaNYuanY2004Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil)Drug Metab Dispos322677114744950
   PubMed Web of Science ®Google Scholar
• GleissnerBSchillingAAnagnostopolousI2004Improved outcome of zygomycosis in patients with hematological diseases?Leuk Lymphoma4513516015359632
   PubMed Web of Science ®Google Scholar
• GreenbergRNMullaneKvan BurikJA2006Posaconazole as salvage therapy for zygomycosisAntimicrob Agents Chemother501263316377677
   PubMed Web of Science ®Google Scholar
• GrollAHWalshTJ2005Posaconazole: clinical pharmacology and potential for management of fungal infectionsExpert Rev Anti Infect Ther34678716107193
   PubMedGoogle Scholar
• GubbinsPO2007Mould-active azoles: pharmacokinetics, drug interactions in neutropenic patientsCurr Opin Infect Dis205798617975407
   PubMed Web of Science ®Google Scholar
• GubbinsPOKrishnaGSansone-ParsonsA2006Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipientsAntimicrob Agents Chemother501993916723557
   PubMed Web of Science ®Google Scholar
• GudlaugssonOGillespieSLeeK2003Attributable mortality of nosocomial candidemia, revisitedClin Infect Dis371172714557960
   PubMed Web of Science ®Google Scholar
• HerbrechtRDenningDWPattersonTF2002Voriconazole versus amphotericin B for primary therapy of invasive aspergillosisN Engl J Med3474081512167683
   PubMed Web of Science ®Google Scholar
• HofH2006A new, broad-spectrum azole antifungal: posaconazole–mechanisms of action and resistance, spectrum of activityMycoses49Suppl 12616961575
   PubMed Web of Science ®Google Scholar
• KrieterPFlanneryBMusickT2004Disposition of posaconazole following single-dose oral administration in healthy subjectsAntimicrob Agents Chemother4835435115328123
   PubMed Web of Science ®Google Scholar
• KwonDSMylonakisE2007Posaconazole: a new broad-spectrum anti-fungal agentExpert Opin Pharmacother811677817516880
   PubMed Web of Science ®Google Scholar
• LinSJSchranzJTeutschSM2001Aspergillosis case-fatality rate: systematic review of the literatureClin Infect Dis323586611170942
   PubMed Web of Science ®Google Scholar
• LupettiADanesiRCampaM2002Molecular basis of resistance to azole antifungalsTrends Mol Med8768111815273
   PubMed Web of Science ®Google Scholar
• MaertensJ2007Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignanciesEur J Haematol782758217241370
   PubMed Web of Science ®Google Scholar
• MaertensJRaadIPetrikkosG2004Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapyClin Infect Dis3915637115578352
   PubMed Web of Science ®Google Scholar
• MarrKACarterRACrippaF2002Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipientsClin Infect Dis349091711880955
   PubMed Web of Science ®Google Scholar
• MarrKASeidelKWhiteTC2000Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazoleJ Infect Dis1813091610608780
   PubMed Web of Science ®Google Scholar
• MetcalfSCDockrellDH2007Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hostsJ Infect552879917697716
   PubMed Web of Science ®Google Scholar
• Mora-DuarteJBettsRRotsteinC2002Comparison of caspofungin and amphotericin B for invasive candidiasisN Engl J Med3472020912490683
   PubMed Web of Science ®Google Scholar
• MunayyerHKMannPAChauAS2004Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and moldsAntimicrob Agents Chemother483690615388421
   PubMed Web of Science ®Google Scholar
• PaganoLCairaMCandoniA2006The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 studyHaematologica9110687516885047
   PubMed Web of Science ®Google Scholar
• PappasPG2006Invasive candidiasisInfect Dis Clin North Am2048550616984866
   PubMed Web of Science ®Google Scholar
• PappasPGRexJHLeeJ2003A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patientsClin Infect Dis376344312942393
   PubMed Web of Science ®Google Scholar
• PfallerMAJonesRNMesserSA1998National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE ProgramDiagn Microbiol Infect Dis31327329597393
   PubMed Web of Science ®Google Scholar
• PfallerMAMesserSABoykenL2004In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance programDiagn Microbiol Infect Dis48201515023430
   PubMed Web of Science ®Google Scholar
• PfallerMAMesserSABoykenL2005Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004)J Clin Microbiol432163715872236
   PubMed Web of Science ®Google Scholar
• PfallerMAMesserSAHollisRJ2001In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformansAntimicrob Agents Chemother452862411557481
   PubMed Web of Science ®Google Scholar
• PfallerMAMesserSABoykenL2008Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance programJ Clin Microbiol46551918094129
   PubMed Web of Science ®Google Scholar
• PitisuttithumPNegroniRGraybillJR2005Activity of posaconazole in the treatment of central nervous system fungal infectionsJ Antimicrob Chemother567455516135526
   PubMed Web of Science ®Google Scholar
• RaadIIGraybillJRBustamanteAB2006aSafety of long-term oral posaconazole use in the treatment of refractory invasive fungal infectionsClin Infect Dis4217263416705579
   PubMed Web of Science ®Google Scholar
• RaadIIHachemRYHerbrechtR2006bPosaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditionsClin Infect Dis42139840316619151
   PubMed Web of Science ®Google Scholar
• RaadIIHannaHABoktourM2008Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofunginLeukemia2249650318094720
   PubMed Web of Science ®Google Scholar
• RamsewakSFKutiJLNicolauDP2005Focus on posaconazole: A novel triazole antifungal for the treatment of invasive fungal infectionsFormulary401321
   Google Scholar
• RodenMMZaoutisTEBuchananWL2005Epidemiology and outcome of zygomycosis: a review of 929 reported casesClin Infect Dis416345316080086
   PubMed Web of Science ®Google Scholar
• SaagMSGraybillRJLarsenRA2000Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of AmericaClin Infect Dis307101810770733
   PubMed Web of Science ®Google Scholar
• SabatelliFPatelRMannPA2006In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeastsAntimicrob Agents Chemother5020091516723559
   PubMed Web of Science ®Google Scholar
• SkiestDJVazquezJAAnsteadGM2007Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infectionClin Infect Dis446071417243069
   PubMed Web of Science ®Google Scholar
• StaberPLangnerSDornbuschHJ2007Antifungal management in cancer patientsWien Med Wochenschr1575031018030555
   PubMedGoogle Scholar
• SunQNFothergillAWMcCarthyDI2002In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetesAntimicrob Agents Chemother461581211959605
   PubMed Web of Science ®Google Scholar
• TorresHAHachemRYChemalyRF2005Posaconazole: a broad-spectrum triazole antifungalLancet Infect Dis57758516310149
   PubMed Web of Science ®Google Scholar
• UllmannAJLiptonJHVesoleDH2007Posaconazole or fluconazole for prophylaxis in severe graft-versus-host diseaseN Engl J Med3563354717251530
   PubMed Web of Science ®Google Scholar
• UptonAKirbyKACarpenterP2007Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortalityClin Infect Dis445314017243056
   PubMed Web of Science ®Google Scholar
• van BurikJAHareRSSolomonHF2006Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 casesClin Infect Dis42e616516511748
   PubMed Web of Science ®Google Scholar
• VazquezJASkiestDJNietoL2006A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDSClin Infect Dis4211798616575739
   PubMed Web of Science ®Google Scholar
• VazquezJASkiestDJTissot-DupontH2007Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infectionHIV Clin Trials8869717507324
   PubMed Web of Science ®Google Scholar
• WalshTJAnaissieEJDenningDW2008Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of AmericaClin Infect Dis463276018177225
   PubMed Web of Science ®Google Scholar
• WalshTJHiemenzJWSeibelNL1998Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 casesClin Infect Dis261383969636868
   PubMed Web of Science ®Google Scholar
• WalshTJRaadIPattersonTF2007Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trialClin Infect Dis4421217143808
   PubMed Web of Science ®Google Scholar
• WalshTJTepplerHDonowitzGR2004Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropeniaN Engl J Med351139140215459300
   PubMed Web of Science ®Google Scholar
• WexlerDCourtneyRRichardsW2004Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover studyEur J Pharm Sci216455315066665
   PubMed Web of Science ®Google Scholar
• WisplinghoffHBischoffTTallentSM2004Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance studyClin Infect Dis393091715306996
   PubMed Web of Science ®Google Scholar
• XiaoLMadisonVChauAS2004Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole bindingAntimicrob Agents Chemother485687414742211
   PubMed Web of Science ®Google Scholar
• ZoniosDIBennettJE2008Update on azole antifungalsSemin Respir Crit Care Med2919821018366001
   PubMed Web of Science ®Google Scholar